Your rights 2013-2018

1. Screening

Based on an upfront agreed programme plan, your selected Target Programme is screened against those compounds that are available within the Joint European Compound Library (JECL). Any ’threshold active’ hits are then identified for further characterization and hit qualification. All experimental work is performed by consortium partners in the European Screening Centre (ESC), supported by IMI funding. Your input may include assay materials (DNA plasmids, proteins etc) and hands-on experience with the assay for trouble-shooting. European Screening Centre scientists will give you a ‘Qualified Hit List’ (QHL) of up to 50 compounds. Where meaningful, the QHL might also contain inactive structural analogues of threshold active hits, to provide a potential structure-activity relationship. In agreement with you as the programme owner and at discretion of the European Screening Centre, the ESC may also undertake additional activities (like resynthesis, DMPK, crystallography) that lead to an ‘Improved Hit List’ (IHL).

2. Access Rights

You will receive the access rights (or in case of IHL compounds even ownership) and 3-year exclusivity to progress QHL/IHL results. In order to give you enough time to progress to a potentially patentable set of data, all threshold active compounds disclosed in your QHL are made unavailable to other target programmes within the EU Lead Factory. During the ‘exclusivity period’ you are under no obligation to disseminate/publish screening results.

3. Exploitation

You are free to decide for your own Target Programme how results (in part or whole) will be advanced, for example by direct exploitation and/or research use. Please note that publication of results is subject to an option right for licensing granted to EFPIA Participants and the publication policy of the European Lead Factory as detailed under the obligations.